Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-30 pm EDT
163.36 USD   -0.71%
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
165.7(c) 164.94(c) 166.36(c) 164.53(c) 163.36(c) Last
8 735 455 8 686 684 8 661 065 7 008 279 8 985 190 Volume
-0.61% -0.46% +0.86% -1.10% -0.71% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash position 2022 9 791 M - -
P/E ratio 2022 20,0x
Yield 2022 2,68%
Sales 2023 99 008 M - -
Net income 2023 23 453 M - -
Net cash position 2023 22 323 M - -
P/E ratio 2023 18,1x
Yield 2023 2,83%
Capitalization 430 B 430 B -
EV / Sales 2022 4,39x
EV / Sales 2023 4,11x
Nbr of Employees 141 700
Free-Float 84,2%
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.5%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems,... 
Sector
Pharmaceuticals
Calendar
10/18Earnings Release
More about the company
Ratings of Johnson & Johnson
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOHNSON & JOHNSON
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the L..
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
BU
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
CI
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
09/20No, Covid Vaccines Don't Cause Body to Produce Toxic Spike Proteins That Cause Cancer
AQ
09/20Johnson & Johnson Sets Up New R&D Facility in San Francisco Bay Area
MT
09/20Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco..
BU
09/20Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area
DJ
More news
News in other languages on JOHNSON & JOHNSON
09/28Johnson & Johnson déclare que la future société de santé grand public s'appellera Kenvu..
09/27Le médicament anticancéreux Carvykti de Legend Biotech obtient l'approbation du Japon p..
09/26Wall Street en ordre dispersé, la nervosité prend le dessus
09/26ANALYSEN DES TAGES von Dow Jones Newswires (26.09.2022)
09/24Enquête en France sur des implants vaginaux pour tromperie et blessures
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
ETFs positioned on JOHNSON & JOHNSONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Nomura NEXT FUNDS International Equity MSCI...12.91%-3.75%-World
HSBC USA SUSTAINABLE EQUITY - Acc - USD11.52%-0.69%-United_States
HSBC USA SUSTAINABLE EQUITY UCITS (dist) ETF - USD10.57%-0.46%-United_States
IShares U.S. Healthcare ETF - USD9.36%-0.83%-NC
SPDR S&P U.S. Health Care Select Sector - USD9.17%1.10%United_States
More ETFs positioned on JOHNSON & JOHNSON
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 163,36 $
Average target price 185,07 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296
NOVO NORDISK A/S3.59%227 057